492 related articles for article (PubMed ID: 29352859)
1. Is selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
[TBL] [Abstract][Full Text] [Related]
2. Side effects associated with current and prospective antimigraine pharmacotherapies.
González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
[TBL] [Abstract][Full Text] [Related]
3. Targeting the 5-HT
Huang PC; Yang FC; Chang CM; Yang CP
Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
[TBL] [Abstract][Full Text] [Related]
4. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
5. Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT
Edvinsson JCA; Maddahi A; Christiansen IM; Reducha PV; Warfvinge K; Sheykhzade M; Edvinsson L; Haanes KA
J Headache Pain; 2022 Feb; 23(1):26. PubMed ID: 35177004
[TBL] [Abstract][Full Text] [Related]
6. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
[TBL] [Abstract][Full Text] [Related]
7. Targeted 5-HT
Vila-Pueyo M
Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
9. Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
[TBL] [Abstract][Full Text] [Related]
10. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
11. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.
Hougaard A; Tfelt-Hansen P
Expert Opin Drug Metab Toxicol; 2015; 11(9):1409-18. PubMed ID: 26095133
[TBL] [Abstract][Full Text] [Related]
12. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
[TBL] [Abstract][Full Text] [Related]
13. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
14. Characterization of binding, functional activity, and contractile responses of the selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Haanes KA; van den Bogaerdt A; Bogers AJJC; Zanelli E; Meeus L; Danser AHJ; Gralinski MR; Senese PB; Johnson KW; Kovalchin J; Villalón CM; MaassenVanDenBrink A
Br J Pharmacol; 2019 Dec; 176(24):4681-4695. PubMed ID: 31418454
[TBL] [Abstract][Full Text] [Related]
15. Serotonin receptor ligands: treatments of acute migraine and cluster headache.
Goadsby PJ
Handb Exp Pharmacol; 2007; (177):129-43. PubMed ID: 17087122
[TBL] [Abstract][Full Text] [Related]
16. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.
van Hoogstraten WS; MaassenVanDenBrink A
J Headache Pain; 2019 May; 20(1):54. PubMed ID: 31096904
[TBL] [Abstract][Full Text] [Related]
17. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
Villalón CM; VanDenBrink AM
Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of the 5-HT1B/1D receptor agonists.
Tepper SJ; Rapoport AM; Sheftell FD
Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
[TBL] [Abstract][Full Text] [Related]
19. Targeting CGRP and 5-HT
Moreno-Ajona D; Chan C; Villar-Martínez MD; Goadsby PJ
Headache; 2019 Jul; 59 Suppl 2():3-19. PubMed ID: 31291016
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
de Vries T; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
